Cyclooxygenase in epilepsy: From perception to application

Drugs of Today

Volumn 45, Issue 2, 2009, Pages 135-154

  Kulkarni, S K ^a   Dhir, Ashish ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPAM; ETODOLAC; ETORICOXIB; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; LUMIRACOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NAPROXEN; NIMESULIDE; PARECOXIB; PENTETRAZOLE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; TENOXICAM; TIAGABINE; TOLMETIN; UNINDEXED DRUG; VALDECOXIB;

ACUTE HEART INFARCTION; ARACHIDONIC ACID METABOLISM; ARTICLE; BRAIN CORTEX; DRUG EFFECT; DRUG MECHANISM; DUODENUM ULCER; ENZYME INHIBITION; EPILEPSY; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; KINDLING; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEIZURE; STOMACH ULCER; TISSUE DISTRIBUTION;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; EPILEPSY; ISOENZYMES;

EID: 66249132320     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.2.1322481     Document Type: Article

References (135)

1. Jacoby., A., Snape, D., Baker, G.A. Epilepsy and social identity: The stigma of a chronic neurological disorder. Lancet Neurol 2005, 4(3): 171-8.
2. McNamars, J.O. Drugs effective in the therapies of epilepsy. In: Hardman, J.C., Limbird, L.E., Gilman, A.G. (Eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics, Vol. 9. McGraw Hill: USA 1996, 521-46.
3. Maida, M.E., O'Banion, M.K. The cyclooxygenase in neuroin-flammation and neurodegeneration: Emerging perspectives. In: Bondy, S.C., Campbell, A. (Eds). Inflammatory Events in Neurodegeneration. Prominent Press: Scottsdale 2001, 158-89.
4. Rogers, J., Mastroeni, D., Leonard, B., Joyce, J., Grover, A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: Are microglia pathogenic in either disorder? Int Rev Neurobiol 2007, 82: 235-46.
5. Centonze, D., Rnazzi-Agrò, A., Bernardi, G., Maccarrone, M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 2007, 28(4): 180-7.
6. Whitton, P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007,150(8): 963-76.
7. Mancuso, C., Perluigi, M., Cini, C., De Marco, C., Giuffrida Stella, A.M., Calabrese, V. Heme oxygenase and cyclooxygenase in the central nervous system: A functional interplay. J Neurosci Res 2006, 84(7): 1385-91.
8. Dhir, A., Padi, S.S., Naidu, PS., Kulkarni, S.K. Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. Eur J Pharmacol 2006, 535(1-3): 192-8.
9. Dhir, A., Naidu, P.S., Kulkarni, S.K. Effect of rofecoxib, a cyclooxygenase-2 inhibitor on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice. Fundam Clin Pharmacol 2006, 20(3): 255-61.
10. Dhir, A., Naidu, P.S., Kulkarni, S.K. Effect of naproxen, a nonselective cyclo-oxygenase inhibitor on pentylenetetrazol-induced kindling in mice. Clin Exp Pharmacol Physiol 2005, 32(7): 574-84.
11. Dhir, A., Naidu, P.S., Kulkarni, S.K. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict Biol 2005,10(4): 329-35.
12. Bazan, N.C. COX-2 as a multifunctional neuronal modulator. Nat Med 2001, 7(4): 414-5.
13. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63(9): 901-10.
14. Kulkarni, S.K., Jain, N.K., Singh, A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol 2000, 22(5): 291-8.
15. Jabbour, H.N., Sales, K.J., Smith, O.P., Battersby, S., Boddy, S.C. Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 2006, 252(1-2): 191-200.
16. Copeland, R.A., Williams, J.M., Giannaras, J. et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994, 91(23): 11202-6.
17. Vane, J.R., Mitchell, J.A., Appleton, I. et al. Inducible iso-forms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994, 91(6): 2046-50.
18. Smith, W.L., DeWitt D.L., Caravito R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-82.
19. Smith, W.L., Dewitt, D.L Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996, 62:167-215.
20. Hawkey, C.J. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 2001,15(5): 801-20.
21. Zhang, J., Rivest, S. Anti-inflammatory effects of prostaglandin E2 in the central nervous system in response to brain injury and circulating Hpopolysaccharide. J Neurochem 2001, 76(3): 855-64.
22. Lin, H., Lin, T.N., Cheung, W.M. et aLCyc/ooxygenase-) and bicistronic cyclooxygenase-!/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002,105(16): 1962-9.
23. anion, M.K. COX-2 and Alzheimer's disease: Potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 1999, 8(10): 1521-36.
24. Manev, H., Uz, T., Qu, T. 5-Lipoxygenase and cyclooxygenase mRNA expression in rat hippocampus: Early response to glu-tamate receptor activation by kainate. Exp Gerontol 2000, 35(9-10): 1201-9.
25. Bazan, N.G., Fletcher, B.S., Herschman, H.R., Mukherjee, P.K. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 1994, 91(12): 5252-6.
26. Nogawa, S., Zhang, F., Ross, M.E., ladecola, C. Cydooxygease-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997,17(8): 2746-55.
27. Luo, J., Lang, J.A., Miller, M.W. Transforming growth factor beta 7 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons. J Neurochem 1998, 71(2): 526-34.
28. Hurley, S.D., Olschowka, J.A., O'Banion, M.K. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 2002,19(1): 1-15.
29. Lipsky, P. Cyclooxygenase-2 specificity and its clinical implication. Am J Med 1999,106(5B): 43S-50S.
30. Marcheselli, V.L., Bazan, N.G. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem 1996, 271(40): 24794-9.
31. Bazan, N.G., Fletcher, B.S., Herschman, H.R., Mukherjee, P.K. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 1994, 91(12): 5252-6.
32. Kukreja, R.C., Kontos, H.A., Hess, M.L., Ellis, E.F. PGH synthase and lipoxygenase generate superoxide in the presence of NADH orNADPH. Circ Res 1986, 59(6): 612-9.
33. McCown, T.J., Knapp, D.J., Crews, FT. Inferior collicular seizure generalization produces site-selective cortical induction of cyclooxygenase 2 (COX-2). Brain Res 1997, 767(2): 370-4.
34. Davies, N.M., Good, R.L., Roupe, K.A., Yanez, J.A. Cyclooxygenase-3: Axiom, dogma, anomaly, enigma or splice error? - Not as easy as 1,2,3. J Pharm Pharm Sci 2004, 7(2): 217-26.
35. Willoughby, D.A., Moore, A.R., Colville-Nash, P.R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000, 355(9204): 646-8.
36. Kis, B., Snipes, J.A., Busija, D.W. Acetaminophen and the cyclooxygenase-3 puzzle: Sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005, 315(1): 1-7.
37. Hinz, B., Cheremina, 0., Brune, K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008, 22(2): 383-90.
38. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231(25): 232-5.
39. Ranga, G.S., Kalra, O.P., Tandon, H., Gambhir, J.K., Mehrotra, G. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2007,16(5): 220-4.
40. Colwell, J.A. Aspirin for the primary prevention of cardiovascular events. Timely Top Med Cardiovasc Dis 2006,10: E25.
41. Dubois RW, Melmed GY, Henning JM, Bernal M. Risk of upper gastrointestinal injury and events in patients treated with cyclooxygenase (COX)-i/COX-2 nonsteroidal antiinflammatory drugs (NSAIDs), COX-2 selective NSAIDs, and gastroprotective cotherapy. An appraisal of the literature. J Clin Rheumatol 2004,10(4): 178-89.
42. Bennett, A., Villa, G. Nimesulide: An NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother 2000, 1(2): 277-86.
43. Kulkami, S.K., Jain, N.K. Coxibs: The new super aspirins or unsafe pain killers? Indian J Pharmacol 2005, 37(2): 86-9.
44. Bombardier, C, Laine, L, Reicin, A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Croup. N Engl J Med 2000,343(21): 1520-8.
45. Rahme, E., Watson, D.J., Kong, S.X., Toubouti, Y., LeLorier, J. Association between non-naproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: A retrospective cohort study. Pharmacoepidemiol Drug Saf 2007,16(5): 493-503.
46. Solomon, D.H., Schneeweiss, S., Glynn, R.J. et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004,109(17): 2068-73.
47. Johnsen, S.P., Larsson, H., Tarone, R.E. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch Intern Med 2005,165(9): 978-84.
48. Tsuborkura, S., Watanabe, Y., Ehara, H. et al. Localization of prostaglandin endoperoxide synthase in neurons and glia in monkey brain. Brain Res 1991, 543(1): 15-24.
49. Yamagata, K., Andreasson, K.I., Kaufmann, W.E., Barnes, C.A. Worley, PR Expression of a mitogen inducible cyclooxy-genase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993,11(2): 371-86.
50. Kawasaki, M., Yoshihara, Y, Yamaji, M., Watanabe, Y. Expression of prostaglandin endoperoxide synthase in rat brain. Mol Brain Res 1993,19(1-2): 39-46.
51. Hewett, S.J., Uliasz, T.F., Vidwans, A.S., Hewett, J.A. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 2000, 293(2): 417-25.
52. Norton, J.L., Adamsom, S.L., Bocking, A.D., Han, V.K.M. Prostaglandin-H synthase-! (PGHS-1) gene is expressed in specific neurons of the brain of the late gestation ovine fetus. Brain Res Dev Brain Res 1996, 95(1): 79-96.
53. Tu, B., Bazan, N.G. Hippocampal kindling epileptogenesis upregulates neuronal cyclooxygenase-2 expression in neocortex. Exp Neurol 2003,179(2): 167-75.
54. Breder, CD., Witt, D., Kraig, R.P. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995, 355(2): 296-315.
55. Kim, E.J., Lee, J.E., Kwon, K.J., Lee, S.H., Moon, C.H., Baik, E.J. Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E(2) production and neurode-generation in cortical and hippocampal cell cultures. Brain Res 2001, 908(1): 1-9.
56. Harris, R.H., Ramwell, P.W., Gilmer, P.J. Cellular mechanism of prostaglandin action. Annu Rev Physiol 1979, 41: 653-8.
57. Folco, G.C., Longiave, D., Bosisio, E. Relation between prostaglandins E2, F2 and cyclic nucleotides levels in rat brain and induction of convulsions. Prostaglandins 1977, 13(5): 893-900.
58. Clark, G.D., Happel, L.T., Zorumski, C.F., Bazan, N.Z. The role of platelet activating factor in the release of excitotoxic neurotransmitters. J Lipid Mediat Cell Signal 1994,10:95-7.
59. Ristori, C, Cammalleri, M., Martini, D. et al.The cyclooxyge-nase-2/ 'prostaglandin E(2) pathway is involved in the somatostatin-induced decrease of epileptiform bursting in the mouse hippocampus. Neuropharmacology 2008, 54(5): 874-84.
60. Bhaduri, J., Hota, D., Acharya, S.B. Role of prostaglandin synthesis inhibitors on chemically induced seizures. Indian J Exp Bioll995, 33(9): 677-81.
61. Takemiya, T., Suzuki, K., Sugiura, H. et al. Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling. Prostaglandins Other Lipid Mediat 2003,71(3-4): 205-16.
62. Chen, C, Bazan, N.G. Lipid signaling: Sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 2005, 77(1-4): 65-76.
63. Oliveira, M.S., Furian, A.F., Royes, L.F. et al. Cyclooxygen-ase-2/ PCE(2) pathway facilitates pentylenetetrazol-induced seizures. Epilepsy Res 2008, 79(1): 14-21.
64. Oliveira, M.S., Furian, A.F., Rambo, L.M. et al. Modulation of pentylenetetrazol-induced seizures by prostaglandin E(2) receptors. Neuroscience 2008,152(4): 1110-8.
65. Akarsu, E.S., Mamuk, S., Comert, A. Inhibition of pentylenetetrazol- induced seizures in rats by prostaglandin D2. Epilepsy Res 1998, 30(1): 63-8.
66. 6 enzymes by convulsant hydrazides. J Pharmacol Exp Ther 1957,119(2): 255-62.
67. Fujiwara-Tsukamoto, Y, Isomura, Y, Imanishi, M., Fukai, T., Takada, M. Distinct types of ionic modulation of GABA actions in pyramidal cells and interneurons during electrical induction of hippocampal seizure-like network activity. Eur J Neurosci 2007, 25(9): 2713-25.
68. Kulkarni, S.K. gamma-Amino butyric acid (GABA) mediated behavioural studies. In: Kulkarni, S.K. (Eds.). Developments in Psychopharmacology, Vol 1. Satish Serial Publishing House: Delhi 2006,15-53.
69. Nutt, D. QABA-A receptors: Subtypes, regional distribution, and function. J Clin Sleep Med 2006,2(2): S7-S11.
70. Schumacher, M., McEwen, B.S. Steroid and barbiturate modulation of the GABA-A receptor. Possible mechanisms. Mol Neurobiol 1989,3(4): 275-304.
71. Sieghart, W. CABA-A benzodiazepine receptors and epilepsy. Wien Klin Wochenschr 1990,102(7): 197-201.
72. Mohler, H., Benke, D., Benson, J., Lüscher, B., Fritschy, J.M. CABA-A receptor subtypes in vivo: Cellular localization, pharmacology and regulation. Adv Biochem Psychopharmacol 1995, 48:41-56.
73. Holland, K.D., McKeon, A.C., Canney, D.J., Covey, D.F., Ferrendelli, J.A. Relative anticonvulsant effects of CABA mimetic and CABA modulatory agents. Epilepsia 1992, 33(6): 981-6.
74. Coulter, D.A., Huguenard, J.R., Prince, D.A. Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: CABA current blockade. Br J Pharmacol 1990,100(4): 807-13.
75. Kulkami, S.K., Ticku, M.K. R015-4513 but not FC-7142 reverses anticonvulsant effects of ethanol against bicu-culline- and picrotoxin-induced convulsions in rats. Pharmacol Biochem Behav1989, 32(1): 233-40.
76. Rastogi, S.K., Ticku, M.K. Anticonvulsant profile of drugs which facilitate GABAergic transmission on convulsions mediated by a GABAergic mechanism. Neuropharmacology 1986, 25(2): 175-85.
77. Knapp, D.J, Crews, FT. Induction of cyclooxygenase-2 in brain during acute and chronic ethanol treatment and ethanol withdrawal. Alcoholi Clin Exp Res 1999,23(4): 633-43.
78. Joseph, S.A., Lynd-Balta, E., O'Banion, M.K. et al. Enhanced cyclooxygenase-2 expression in olfactory-limbic forebrain following kainate-induced seizures. Neuroscience 2006, 140(3): 1051-65.
79. Salinska, E., Danysz, W., Lazarewicz, J.W. The role ofexcito-toxicity in neurodegeneration. Folia Neuropathol 2005, 43(4): 322-39.
80. Kaufman, W.E., Worley, P.F., Pegg, J., Bremer, M., Isakson, P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at post synaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996,93(6): 2317-21.
81. Tsai, C, Gastfriend, D.R., Koyle, J.T. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995, 152(3): 332-40.
82. Kulkarni, S.K., Mehta, A.K., Ticku, M.K. Comparison of anticonvulsant effect of ethanol against NMDA-, kainic acid- and picrotoxin-induced convulsions in rats. Life Sci 1990, 46(7): 481-7.
83. Lysz, T.W., Centra, M., Markey, K., Keeting, P.E. Evidence for increased activity of mouse brain fatty acid cyclooxygenase following drug-induced convulsions. Brain Res 1987, 408(1-2): 6-12.
84. Dhir, A., Naidu, P.S., Kulkarni, S.K. Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action. Indian J Exp Biol 2006,44(4): 286-91.
85. Dhir, A., Naidu, P.S., Kulkarni, S.K. Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: Possible mechanism of action. Prog Neuropsychopharma-col Biol Psychiatry 2006,30(8): 1478-85.
86. Wallenstein, M.C., Mauss, E.A. Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats. Pharmacology 1984,29(2): 85-93.
87. Kim, D.K., Jang, T.J. Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure. Int J Exp Pathol 2006, 87(1): 73-8.
88. Akarsu, E.S., Ozdayi, S., Algan, E., Ulupinar, F. The neuronal excitability time-dependently changes after lipopolysaccha-ride administration in mice: Possible role of cyclooxygenase-2 induction. Epilepsy Res 2006,71(2-3): 181-7.
89. Shafiq, N., Malhotra, S., Pandhi, P. Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion. Methods Find Exp Clin Pharmacol 2003, 25(2): 87-90.
90. Braestrup, C, Nielsen, E.B., Sonnewald, U. et al. (R)-N-[4,4-bis(3- methyl-2-thienyl)but-3-en-hyl]nipecotic acid binds with high affinity to the brain GABA uptake carrier. J Neurochem 1990, 54(2): 639-45.
91. Sujdak, P.D.Jansen, J.A. A review of the preclinical pharmacology of tiagabine, a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995, 36(6): 612-26.
92. Picardo, A., Cent, J.P. Feely, M. Anticonvulsant tolerance and recovery during repeated administration of the CABA uptake inhibitor NO-328. Br J Pharmacol 1990, 99:131P.
93. Nielsen, E.B., Suzdak, P.D., Andersen, K.E., Knutsen, L.J., Sonnewald, U., Braestrup, C. Characterization of tiagabine (NO-328), a new potent and selective CABA uptake inhibitor. Eur J Pharmacol 1991,196(3): 257-66.
94. Dhir, A., Kulkarni, S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice. Inflammopharmacology 2006, 14(5-6): 222-5.
95. Ahuja, N., Singh, A., Singh, B. Rofecoxib, an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003, 55(7): 859-94.
96. Dhir, A., Akula, K.K., Kulkarni, S.K. Rofecoxib potentiates the anticonvulsant effect of topiramate. Inflammopharmacology 2008,16(2): 83-6.
97. Nutt, D.J., Cowen, P.J., Green, A.R. Studies on the post-ictal rise in seizure threshold. Eur J PharmacoU981,71(2-3): 287-95.
98. Loscher, W., Honack, D., Fassbendr, C.P., Nolting, B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models. Epilepsy Res 1991, 8(3): 171-89.
99. Akula, K.K., Dhir, A., Kulkarni, S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, increases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism. Epilepsy Res 2008,78(1): 60-70.
100. Coddard, G.V. Development of epileptic seizures through brain stimulation at low intensity. Nature 1967, 214(5092): 1020-1.
101. Goddard, G.V., Douglas, R.M. Does the engram of kindling model the engram of normal long-term memory? In: Wada, J. (Ed.). Kindling. Raven Press: New York 1996,1-18.
102. Barkai, E., Grossman, Y., Gutnick M.J. Long term changes in neocortical activity after chemical kindling with systemic pentylenetetrazol: An in vitro study. J Neurophysiol 1994, 72(1): 72-83.
103. Giorgi, 0., Orlandi, M., Lecca, D., Corda, M.G. MK-801 prevents chemical kindling induced by pentylenetetrazol in rats. Eur J Pharmacol 1991,193(3): 363-5.
104. Leweke, F.M., Louvel, J., Rausche, G., Heinemann, U. Effects of PTZ on neuronal activity and on extracellular calcium concentration in rat hippocampal slices. Epilepsy Res 1990, 6(3): 187-98.
105. Dhir, A., Naidu, P.S., Kulkarni, S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 2007, 16(8): 691-7.
106. Gasior, M., Ungard, J.T., Beekman, M., Carter, R.B., Wihun, J.M. Acute and chronic effects of synthetic neuroactive steroid, ganaxolonè, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: Comparison with diazepam and valproate. Neuropharmacology 2000, 39(7): 1184-96.
107. Sang, N., Chen, C. Lipid signaling and synaptic plasticity. Neuroscientist 2006,12(5): 425-34.
108. Rouzer, C.A., Marnett, L.J. Non-redundant functions of cyclooxygenases: Oxygenation of endocannabinoids. J Biol Chem 2008, 283(13): 8065-9.
109. Kulkarni, S.K., George, B. Significance of long-term potentiation (LTP) in cognitive functions and epilepsy. Indian J Pharmacol 1999, 31:14-22.
110. Croucher, M.J., Collins, J.F., Meldrum, B.S. Anticonvulsant action of excitatory amino acid antagonists. Science 1982, 216(4548): 899-901.
111. McNamara, J.O. Kindling model of epilepsy. Adv Neurol 1986, 44: 303-18.
112. Yang, H., Zhang, J., Andreasson, K., Chen, C. COX-2 oxidative metabolism of endocannabinoids augments hippocam-pal synaptic plasticity. Mol Cell Neurosci 2008 37(4): 682-95.
113. Kunz, T., Oliw, E.H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci 2001a, 13(3): 569-75.
114. Strauss, K.I., Marini, A.M. Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J Neurotrauma 2002,19(5): 627-38.
115. Farooqui, A.A., Ong, W.Y., Horrocks, LA. Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4(1): 85-96.
116. Takemiya, T., Matsumura, K., Yamagata, K. Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem Int 2007, 51(2-4): 112-20.
117. Kawaguchi, K., Hickey, R.W., Rose, M.E., Zhu, L, Chen, J., Graham, S.H. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res 2005, 1050(1-2): 130-7.
118. Kunz, T., Marklund, N., Hillered, L, Oliw, E.H. Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat. Brain Res Cogn Brain Res 2005, 25(3): 826-32.
119. Gobbo, O.L., O'Mara, S.M. Post-treatment, but not pre-treatment, with the selective cyclooxygenase-2 inhibitor cele-coxib markedly enhances functional recovery from kainic acid-induced neurodegeneration. Neuroscience 2004: 125(2): 317-27.
120. Ciceri, P., Zhang, Y., Shaffer, A.F. et al. Pharmacology of celecoxib in rat brain after kainate administration. J Pharmacol Exp Ther 2002, 302(3): 846-52.
121. Kunz, T., Oliw, E.H. Nimesulide aggravates kainic acid-induced seizures in the rat. Pharmacol Toxicol 2001, 88(5): 271-6.
122. Simmet, T, Tippler, B. Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid. Brain Res 1990, 515(1-2): 79-86.
123. Baik, E.J., Kim, E.J., Lee, S.H., Moon, C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999, 843(1-2): 118-29.
124. Yoshikawa, K., Kita, Y, Kishimoto, K., Shimizu, T. Profiling of eicosanoid production in the rat hippocampus during kainic acid-induced seizure: Dual phase regulation and differential involvement of COX-1 and COX-2. J Biol Chem 2006, 281(21): 14663-9.
125. Hashimoto, K., Watanabe, K., Nishimura, T., lyo, M., Shirayama, Y, Minabe, Y. Behavioral changes and expression of heat shock protein hsp-70 mRNA, brain derived neurotrophic factor mRNA, and cyclooxygenase-2 mRNA in rat brain following seizures induced by systemic administration of kainic acid. Brain Res 1998, 804(2): 212-23.
126. Bishnoi, M., Patil, C.S., Kumar, A., Kulkarni, S.K. Co-administration of acetyl-11-keto beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology 2007,79(1): 34-41
127. Kim, H.C., Jhoo, W.K., Bing, G. et al. Phenidone prevents kainate-induced neurotoxicity via antioxidant mechanisms. Brain Res 2000, 874(1): 15-23.
128. Kulkarni, S.K., George, B. Lithium-pilocarpine neurotoxicity: A potential model of status epilepticus. Methods Find Exp Clin Pharmacol 1995,17(8): 551-67.
129. George, B., Kulkarni, S.K., Mathur, R. Motor and electro-graphic response of refractory experimental status epilepticus in rats and effect of calcium channel blockers. Indian J Exp Biol 2000,38(2): 105-12.
130. Voutsinos-Porche, B., Koning, E., Kaplan, H. et al. Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol Dis 2004,17(3): 385-402.
131. Lee, B., Dziema, H., Lee, K.H., Choi, Y.S., Obrietan, K. CRE-mediated transcription and COX-2 expression in the pilocarpine model of status epilepticus. Neurobiol Dis 2007, 25(1): 80-91.
132. Ajmone-Cat, M.A., losif, R.E., Ekdahl, C.T., Kokaia, Z., Minghetti, L., Lindvall, 0. Prostaglandin E2 and BDNFlevels in rat hippocampus are negatively correlated with status epilepticus severity: No impact on survival of seizure-generated neurons. Neurobiol Dis 2006,23(1): 23-35.
133. Jung, K.H., Chu, K., Lee, S.T. et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis 2006, 23(2): 237-46.
134. Okada, K., Yamashita, D., Tsuji, S. Cyclooxygenase system contributes to the maintenance of post convulsive period of epileptic phenomena in the genetically epileptic E1 mice. J UOEH 2006, 28(3): 265-7.
135. Okada, K., Yuhi, T., Tsuji, S., Yamashita, U. Cyclooxygenase-2 expression in the hippocampus of genetically epilepsy susceptible E1 mice was increased after seizure. Brain Res 2001, 894(2): 332-5.